OWM: Please describe the education, training, and work experiences that have prepared you for your current position as Director of Government Affairs and Reimbursement at Smith & Nephew.
I have worked more than 15 years in Biologic and Medical Device Government Affairs and Reimbursement capacities. For 15 years before entering the industry, I held a number of positions within healthcare administration.
OWM: What inspired you to start working with government affairs and reimbursement at Smith & Nephew?
Smith & Nephew enjoys a positive reputation in providing high-quality, patient-focused products. As an industry representative for many years, I continually evaluated the Advanced Wound Management division and was fortunate to secure a position within the organization.
OWM: Please describe the education, training, and work experiences that prepared you for your current position as the CEO of Alliqua.
I attended The Northern Alberta Institute of Technology in Canada, and I am a Fellow of the Wharton School of Business at The University of Pennsylvania. I have been in the medical device industry for more than 30 years, the past 25 leading businesses in small, medium, and large company environments. Most recently before Alliqua, I spent 12 years with ConvaTec (Skillman, NJ), nine of those as the CEO and COO. We had a successful run during those years, building a strong company from $650 million in revenue when I joined in 2000 to $1.7 billion when I left. This was done through the efforts of great people who truly cared about the customer.
OWM: Please describe the education, training, and work experiences that prepared you for your current position at Hollister.
I have been in the wound care industry for more than 20 years, holding various roles in sales, sales training, sales operations, sales management, marketing, business development, strategic development, and portfolio development. Currently, I am General Manager for the Wound Care business of Hollister Incorporated.
Kennedy Terminal Ulcers have been mistaken for elder abuse. This article reviews the literature and recognition relevant to the Kennedy Terminal Ulcer and provides several case studies that underscore classification, care, and outcomes with this end-of-life phenomenon. In one specific situation, a 42-year-old woman caring for her aunt was convicted of a felony and sentenced to 3 years in prison, demonstrating the controversy that persists with regard to the unavoidability of this particular ulcer.
–Joy Schank, RN, MSN, ANP, CWOCN Kennedy Terminal Ulcers have been mistaken for elder abuse. This article reviews the literature and recognition relevant to the Kennedy Terminal Ulcer and provides several case studies that underscore classification, care, and outcomes with this end-of-life phenomenon. In one specific situation, a 42-year-old woman caring for her aunt was convicted of a felony and sentenced to 3 years in prison, demonstrating the controversy that persists with regard to the unavoidability of this particular ulcer.
The Kennedy Terminal Ulcer
History. The Kennedy Terminal Ulcer was first described in modern medical literature by Karen Lou Kennedy in 1989.1 Along with other healthcare workers at the Byron Health Center in Fort Wayne, IN, she noted that despite implementation of appropriate preventive measures, certain patients still exhibited skin breakdown in the sacral/coccygeal area. They further often noted the skin deteriorated rapidly, even during the course of a single day. Caregivers and family members alike were surprised at the sudden onset of this clinical phenomenon. This initial report was based on retrospective chart reviews of individuals with pressure ulcers. Upon further inquiry into how long these individuals lived after occurrence of this type of pressure ulcer, just over half (55.7%) died within 2 weeks to several months of discovery of their pressure ulcer. These observations were further supported by Hanson et al,2 who reported 62.5% of pressure ulcers in hospice patients occurred within 2 weeks of death.
OWM: Please describe the education, training, and work experiences that prepared you for your current position as the president of BSN Medical.
My academic background includes a BA from Shippensburg University (Shippensburg, PA), a Masters from Lehigh University (Bethlehem, PA), and postgraduate business certification from Wharton University of Pennsylvania (Philadelphia, PA). I recently completed a doctoral residency in business with a focus in marketing and adaptive leadership. For the majority of my corporate career (the past 25 years), I have been privileged to work with leading medical companies — Roche Diagnostics, Agilent (formerly Varian), and now BSN Medical. Working in senior executive management globally in a variety of progressively challenging and multidiscipline technologies and markets has prepared me well for my current leadership responsibilities at BSN. I take a lot of pride in the opportunity to work with many talented and committed professionals, with the support of a leading global healthcare company. Based in Charlotte, North Carolina, I am currently responsible for commercial activities for the US and Canada.
OWM: Please describe the education, training, and work experiences that prepared you for your current position as the CEO of Wellsense.
I spent 15 years with General Electric (GE), including 7 years with GE Healthcare. Most of my work was on the business development side, doing mergers and acquisitions. I moved to Israel in 1999 to integrate a couple of businesses GE had acquired there, and later that year I became the national executive, having overall responsibility for GE businesses in Israel. In 2003, I left GE to start MediTech Advisors, a medical device venture fund with two GE colleagues. We transitioned it into a second fund in 2006 with Ziegler Investments, a US Midwest Merchant Banking group. Right before joining Wellsense, I served as CEO of Ovalum Vascular, a medical device company that develops and produces technology designed for arterial conditions.
OWM: Why did you choose to lead this particular company?
I decided I wanted to go back into operations after Ziegler MediTech was fully invested. I started working with a number of entrepreneurs, including Ran Poliakine, the founder of Wellsense, who are invested in a number of medical device companies. Wellsense is one of the companies in that cluster that is in the more advanced stages, and I decided to join them to help build the strategy for the group. After I completed the go-to-market strategy for Wellsense, the board asked me to come on as CEO to implement it.
OWM: Please describe the education, training, and work experiences that prepared you for your current position as the president of DM Systems.
I completed my undergraduate degree at Notre Dame University (South Bend, IN) and went on to medical school at Loyola University (Chicago, IL). I completed my residency at Northwestern Memorial Hospital-Cook County Orthopedic Residency Program. I also have worked as an Assistant Professor of Orthopedic Surgery at Northwestern University Orthopedic Program and spent 35 years as an orthopedic surgeon, including 18 years as Chairman of the Orthopedics Department at St. Francis Hospital in Evanston, IL.
OWM: Please describe the education, training, and work experiences that prepared you for your current position as the executive director of the US Wound Registry (USWR).
During my residency in Family Medicine, I had some exposure to public health research. Back then, we were using paper medical records, and few people were discussing patient registries as a mechanism for research. I became interested in electronic health records in 1995 when the AMA published its 53-page physician documentation guidelines. By then, I was a faculty member of the medical school and we were threatened with pay cuts if we over-coded our services. It was clear to me that only a computer could consistently calculate the level of service correctly, given the complexity of the system. So, in 1995, I began working with a computer programmer to automate the calculation of the physician charges generated in the wound center. By 2000, Intellicure, Inc (College Station, TX) was a company, and David Walker, our CEO, had developed a similar internal calculation system for the hospital facility charges.
Technology originally developed by the US Navy to safely transport specially trained marine mammals outside of water is now being used on hospital beds, stretchers, and in wheelchairs to improve patient care and outcomes.
By emulating the effects of floating, the Dolphin Fluid Immersion Simulation® (FIS) (Joerns Healthcare, LLC, Charlotte, NC) advanced therapy system helps promote tissue perfusion and prevent skin injury related to pressure and shearing forces that compromise blood flow. The advanced surface conforms to the body, minimizing soft tissue deformation, and is available for patients at risk of skin breakdown, particularly during surgical procedures; patients with spinal cord injuries; and patients undergoing flap and graft surgery for wound repair (see Figure 1). The technology is used to prevent pressure ulcers and to advance the healing of complex pressure ulcers, surgical flaps, skin grafts, burns, and other wound conditions.